✦ LIBER ✦

PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

✍ Scribed by E Orlewska; P Mierzejewski; A Czlonkowska

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND8 COST-EFFECTIVENESS AND BUDGET IMPAC

✍ O Espallardo; C Crespo; C Polanco; D Nieves 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

PND8 COST-EFFECTIVENESS ANALYSIS OF REBI

✍ MJ Nuijten; T Mittendorf; A Jäcker; U Osowski 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

PND13 A COST-EFFECTIVENESS ANALYSIS OF N

✍ R Gani; ER Samuels; S Hughes; G Giovanonni 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PND35 Belgian Cost-Utility Analysis of G

✍ S. Drieskens; K. Moeremans 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND28 Cost-Effectiveness Analysis of Int

✍ R. Sánchez-de la Rosa; E. Sabater; M.A. Casado 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PND2 Cost Offsets and Gains in Health Ef

✍ M. Ekman; R.E. White; P.E. Buck; N. Justo; P Lindgren 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB